Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions
Open Access
- 1 May 2007
- journal article
- clinical trial
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (5) , 527-537
- https://doi.org/10.1128/cvi.00435-06
Abstract
The enzyme-linked immunospot (ELISPOT) assay is a powerful tool for measuring antigen-specific cellular immune responses. The ability to use frozen peripheral blood mononuclear cells (PBMC) facilitates testing samples in multicenter clinical trials; however, unreliable ELISPOT responses may result if samples are not handled properly. Exposure of frozen PBMC to suboptimal storage temperature (−20°C) or repeated cycling between more optimal storage temperatures (less than −130°C and −70°C) reduced the quality of frozen PBMC, as assessed by cell viability and functional ELISPOT response measures. Cell viability as assessed by trypan blue dye exclusion was reduced, and the percentage of apoptotic cells, as determined by the Guava Nexin assay, was significantly increased after these events. The functional gamma interferon ELISPOT responses to phytohemagglutinin (PHA) mitogen, a CD4 T-cell-specific antigen (varicella-zoster virus), and a CD8 T-cell-specific antigen (pool containing known cytomegalovirus, Epstein-Barr virus, and influenza virus peptides) were all significantly reduced after suboptimal storage events. However, for a given suboptimal storage event, the magnitude of the reduction varied between individuals and even among aliquots within an individual bleed, indicating the need for sample-specific acceptance criteria (AC). The percent viable or percent apoptotic cells after thaw, as well as the functional ELISPOT response to PHA, were all effective when applied with limits as AC for separating samples damaged during storage from valid control samples. Although all three AC measures could be effectively applied, the apoptosis AC limit applied was best for separating samples that could respond to antigenic stimulation from samples that could not effectively respond.Keywords
This publication has 34 references indexed in Scilit:
- Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjectsVaccine, 2006
- Cytomegalovirus‐Specific Immunity and Protection against Viremia and Disease in HIV‐Infected Patients in the Era of Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2006
- Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ ImmunityClinical Cancer Research, 2005
- High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsThe Journal of Infectious Diseases, 2005
- Limited Sequence Evolution within Persistently Targeted CD8 Epitopes in Chronic Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2005
- Memory T-Cell Response to Rotavirus Detected with a Gamma Interferon Enzyme-Linked Immunospot AssayJournal of Virology, 2005
- Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-? ELISPOT assay: Responses in an elderly population receiving a booster immunizationJournal of Medical Virology, 2003
- Cryopreserving human peripheral blood progenitor cells with 5‐percent rather than 10‐percent DMSO results in less apoptosis and necrosis in CD34+ cellsTransfusion, 2002
- Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster VirusClinical and Diagnostic Laboratory Immunology, 2001
- Preservation of Lymphocyte Immunophenotype and Proliferative Responses in Cryopreserved Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Donors: Implications for Multicenter Clinical TrialsClinical and Diagnostic Laboratory Immunology, 2000